Investigating a new target for treating choroideremia, a blinding eye disease.
Retinal Pigment Epithelium Secreted Matrix Metalloproteinase 2 as a Novel Target in Choroideremia
['FUNDING_R01'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-10943011
This study is looking at how a specific protein affects the health of retinal cells in people with choroideremia, a genetic condition that causes vision loss, to find new ways to help treat the disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-10943011 on ClinicalTrials.gov |
What this research studies
This research focuses on choroideremia, a genetic condition that leads to vision loss due to degeneration of retinal cells. The team aims to understand how dysfunction in retinal pigment epithelial (RPE) cells contributes to the disease's progression. By studying the molecular mechanisms involved, particularly the role of a protein called MMP2, they hope to identify new therapeutic targets. The research involves advanced techniques to analyze cellular signaling pathways and their effects on retinal health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with choroideremia, particularly those experiencing early symptoms of vision loss.
Not a fit: Patients with other forms of retinal degeneration unrelated to choroideremia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow or prevent vision loss in patients with choroideremia.
How similar studies have performed: Previous research has shown promise in targeting similar molecular pathways in other retinal diseases, suggesting potential for success in this approach.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FAHIM, ABIGAIL — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: FAHIM, ABIGAIL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.